Gufic BioSciences wins appeal against ₹4.33 crore tax demand
- Gufic BioSciences won an appeal against a ₹4.33 crore income tax demand for AY 2024-25
- The Commissioner of Income Tax (Appeals) passed the order on September 28, 2026
- The demand arose from disallowance of expenditure under Section 143 of the Income Tax Act
- The order results in the complete deletion of the ₹4.33 crore liability
*this image is generated using AI for illustrative purposes only.
Gufic BioSciences has secured a favourable appellate order from the Commissioner of Income Tax (Appeals), leading to the deletion of an income tax demand of ₹4.33 crore for the Assessment Year 2024-25.
The order, dated September 28, 2026, and received by the company on September 29, 2026, allowed the appeal filed against a demand raised under Section 143 of the Income Tax Act, 1961. The original demand arose due to disallowance of expenditure during the assessment process.
Regulatory Disclosure Details
The company informed BSE and NSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure follows an earlier intimation dated January 20, 2026.
| Particulars | Details |
|---|---|
| Authority | Commissioner of Income Tax (Appeals) |
| Order Date | September 28, 2026 |
| Receipt Date | September 29, 2026 |
| Demand Amount | ₹4,33,36,680 |
| Assessment Year | AY 2024-25 |
Impact on Financial Position
Upon giving effect to the appellate order, the income tax demand of ₹4.33 crore will be deleted from the company's books. This outcome removes a significant contingent liability that had been provisioned or disclosed in prior financial statements for the Assessment Year 2024-25.
What the Numbers Show
The complete allowance of the appeal indicates that the tax authority accepted Gufic BioSciences' position regarding the disallowance of expenditure. The resolution of this ₹4.33 crore dispute eliminates the associated litigation risk and potential cash outflow, thereby strengthening the company's balance sheet health for the current fiscal year.
Historical Stock Returns for Gufic BioSciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.83% | +0.20% | +7.43% | +55.64% | +21.93% | +123.16% |
How will the reversal of the ₹4.33 crore provision impact Gufic BioSciences' reported net profit for the current fiscal quarter?
Does this favorable appellate outcome suggest a broader trend of tax authorities relaxing scrutiny on pharmaceutical expenditure disallowances?
Will the freed-up capital be allocated toward R&D expansion or debt reduction in the upcoming financial planning cycle?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
